{{Drugbox
| verifiedrevid = 461093764
| IUPAC_name = 1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
| image = Enoxacin.svg
<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|monograph|oxistat}}
| MedlinePlus = a601013
| routes_of_administration = Oral
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 74011-58-8
| ATC_prefix = J01
| ATC_suffix = MA04
| PubChem = 3229
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00467
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 3116
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 325OGW249P
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00310
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 157175
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 826
<!--Chemical data-->
| C=15 | H=17 | F=1 | N=4 | O=3
| molecular_weight = 320.319 g/mol
| smiles = Fc1c(nc2c(c1)C(=O)C(\C(=O)O)=C/N2CC)N3CCNCC3
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C15H17FN4O3/c1-2-19-8-10(15(22)23)12(21)9-7-11(16)14(18-13(9)19)20-5-3-17-4-6-20/h7-8,17H,2-6H2,1H3,(H,22,23)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = IDYZIJYBMGIQMJ-UHFFFAOYSA-N
}}
'''Enoxacin'''<ref group=note>Enoxacin is sold under the following trade names: '''Almitil''', '''Bactidan''', '''Bactidron''', '''Comprecin''', '''Enoksetin''', '''Enoxen''', '''Enroxil''', '''Enoxin''', '''Enoxor''', '''Flumark''', '''Penetrex''', '''Gyramid''', '''Vinone'''.</ref> is an oral broad-spectrum [[fluoroquinolone]] [[antibacterial]] agent used in the treatment of [[urinary tract infection]]s and [[gonorrhea]]. [[Insomnia]] is a common adverse effect.<ref>{{Cite journal  | last1 = Rafalsky | first1 = V. | last2 = Andreeva | first2 = I. | last3 = Rjabkova | first3 = E.  | last4 = Rafalsky  | first4 = Vladimir V | title = Quinolones for uncomplicated acute cystitis in women | journal = Cochrane Database Syst Rev | volume = 3 | issue =  3| pages = CD003597 | date=  2006 | doi = 10.1002/14651858.CD003597.pub2 | editor1-last = Rafalsky  | editor1-first = Vladimir V  |  pmid=16856014}}</ref><ref>{{Cite journal  | last1 = Mogabgab | first1 = WJ. | title = Recent developments in the treatment of sexually transmitted diseases | journal = Am J Med | volume = 91 | issue = 6A | pages = 140S–144S |date=Dec 1991 | doi =  10.1016/0002-9343(91)90327-T| pmid = 1767802 }}</ref> It is no longer available in the [[United States]].

It has been shown recently that it may have cancer inhibiting effect.<ref>http://www.pnas.org/content/early/2011/02/24/1014720108</ref>

== Mechanism of action ==
Quinolones and fluoroquinolones are bactericidal drugs, eradicating bacteria by interfering with DNA replication.
Like other fluoroquinolones, enoxacin functions by inhibiting bacterial [[DNA gyrase]] and [[topoisomerase IV]]. The inhibition of these enzymes prevents bacterial DNA replication, transcription, repair and recombination.<ref name="pmid8388200">{{cite journal |vauthors=Yoshida H, Nakamura M, Bogaki M, Ito H, Kojima T, Hattori H, Nakamura S |title=Mechanism of action of quinolones against Escherichia coli DNA gyrase |journal=Antimicrob. Agents Chemother. |volume=37 |issue=4 |pages=839–45 | date=April  1993 |pmid=8388200 |pmc=187778 |doi= 10.1128/aac.37.4.839|url=http://aac.asm.org/cgi/pmidlookup?view=long&pmid=8388200 |accessdate=2014-09-24}}</ref><ref name="pmid3000292">{{cite journal |vauthors=Wolfson JS, Hooper DC |title=The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro |journal=Antimicrob. Agents Chemother. |volume=28 |issue=4 |pages=581–6 | date=October  1985 |pmid=3000292 |pmc=180310 |doi= 10.1128/aac.28.4.581|url=http://aac.asm.org/cgi/pmidlookup?view=long&pmid=3000292 |accessdate=2014-09-24}}</ref>
Enoxacin is active against many [[Gram-positive bacteria]].<ref group=note>Examples of Gram-positive bacteria include:  [[Klebsiella pneumoniae]], [[Staphylococcus aureus]], [[Staphylococcus epidermidis]], [[Clostridium perfringens]].</ref> The quinolone is also active against [[Gram-negative bacteria]]<ref group=note>Gram-negative bacteria include: [[Acinetobacter]], [[Citrobacter]], [[Campylobacter]], [[Escherichia coli]], [[Haemophilus influenzae]], [[Moraxella catarrhalis]], [[Serratia marcescens]], [[Pseudomonas aeruginosa]], [[Proteus mirabilis]], [[Proteus vulgaris]], [[Salmonella]], [[Shigella flexneri]].</ref><ref name="pmid6229216">{{cite journal |vauthors=Chin NX, Neu HC |title=In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprim |journal=Antimicrob. Agents Chemother. |volume=24 |issue=5 |pages=754–63 | date=November  1983 |pmid=6229216 |pmc=185938 |doi= 10.1128/aac.24.5.754|url=http://aac.asm.org/cgi/pmidlookup?view=long&pmid=6229216 |accessdate=2014-09-24}}</ref><ref name="pmid6586712">{{cite journal |vauthors=Wise R, Andrews JM, Danks G |title=In-vitro activity of enoxacin (CL-919), a new quinoline derivative, compared with that of other antimicrobial agents |journal=J. Antimicrob. Chemother. |volume=13 |issue=3 |pages=237–44 | date=March  1984 |pmid=6586712 |doi= 10.1093/jac/13.3.237|url=http://jac.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=6586712 |accessdate=2014-09-24}}</ref>

== Pharmacokinetics ==
After oral administration enoxacin is rapidly and well absorbed from the gastrointestinal tract. The antibiotic is widely distributed throughout the body and in the different biological tissues. Tissue concentrations often exceed serum concentrations. The binding of enoxacin to serum proteins is 35 to 40%.
The serum elimination half-life, in subjects with normal renal function, is approximately 6 hours. Approximately 60% of an orally administered dose is excreted in the urine as unchanged drug within 24 hours.<ref name="pmid6591851">{{cite journal |vauthors=Wise R, Lockley R, Dent J, Webberly M |title=Pharmacokinetics and tissue penetration of enoxacin |journal=Antimicrob. Agents Chemother. |volume=26 |issue=1 |pages=17–9 | date=July  1984 |pmid=6591851 |pmc=179907 |doi= 10.1128/aac.26.1.17|url=http://aac.asm.org/cgi/pmidlookup?view=long&pmid=6591851 |accessdate=2014-09-24}}</ref><ref name="pmid3463542">{{cite journal |vauthors=Wise R, Lister D, McNulty CA, Griggs D, Andrews JM |title=The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin |journal=Infection |volume=14 Suppl 3 |issue= |pages=S196–202 |year=1986 |pmid=3463542 |doi= 10.1007/bf01667843|url= }}<!--|accessdate=2014-09-24--></ref>
A small amount of a dose of drug administered is excreted in the bile.<ref>Flowerdew, A., E. Walker, and S. J. Karran. "Evaluation of biliary pharmacokinetics of oral enoxacin, a new quinolone antibiotic." 14th International Congress of Chemotherapy, Kyoto. 1985.</ref> High concentrations of the fluoroquinolone are reached in the urinary tract and this fact ensures an antibacterial effect continued over time, particularly in this district.

==Medical uses==
Enoxacin can be used to treat a wide variety of infections, particularly [[gastroenteritis]] including infectious diarrhea, [[respiratory tract infections]], [[gonorrhea]]<ref name="pmid3111354">{{cite journal |vauthors=van der Willigen AH, van der Hoek JC, Wagenvoort JH, van Vliet HJ, van Klingeren B, Schalla WO, Knapp JS, van Joost T, Michel MF, Stolz E |title=Comparative double-blind study of 200- and 400-mg enoxacin given orally in the treatment of acute uncomplicated urethral gonorrhea in males |journal=Antimicrob. Agents Chemother. |volume=31 |issue=4 |pages=535–8 | date=April  1987 |pmid=3111354 |pmc=174773 |doi= 10.1128/aac.31.4.535|url=http://aac.asm.org/cgi/pmidlookup?view=long&pmid=3111354 |accessdate=2014-09-24}}</ref> and [[urinary tract infections]].<ref name="pmid3162900">{{cite journal |vauthors=Huttunen M, Kunnas K, Saloranta P |title=Enoxacin treatment of urinary tract infections in elderly patients |journal=J. Antimicrob. Chemother. |volume=21 Suppl B |issue= |pages=105–11 | date=February  1988 |pmid=3162900 |doi= 10.1093/jac/21.suppl_b.105|url=http://jac.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=3162900 |accessdate=2014-09-24}}</ref><ref name="pmid2764538">{{cite journal |vauthors=Backhouse CI, Matthews JA |title=Single-dose enoxacin compared with 3-day treatment for urinary tract infection |journal=Antimicrob. Agents Chemother. |volume=33 |issue=6 |pages=877–80 | date=June  1989 |pmid=2764538 |pmc=284249 |doi= 10.1128/aac.33.6.877|url=http://aac.asm.org/cgi/pmidlookup?view=long&pmid=2764538 |accessdate=2014-09-24}}</ref>

== Adverse effects ==
Enoxacin, like other fluoroquinolones, is known to trigger [[seizures]] or lower the [[seizure threshold]].<ref name="pmid8395790">{{cite journal |vauthors=De Sarro A, Zappalá M, Chimirri A, Grasso S, De Sarro GB |title=Quinolones potentiate cefazolin-induced seizures in DBA/2 mice |journal=Antimicrob. Agents Chemother. |volume=37 |issue=7 |pages=1497–503 | date=July  1993 |pmid=8395790 |pmc=188001 |doi= 10.1128/aac.37.7.1497|url=http://aac.asm.org/cgi/pmidlookup?view=long&pmid=8395790 |accessdate=2014-09-25}}</ref> The compound should not be administered to patients with [[epilepsy]] or a personal history of previous convulsive attacks as may promote the onset of these disorders.<ref name="pmid2862357">{{cite journal |vauthors=Simpson KJ, Brodie MJ |title=Convulsions related to enoxacin |journal=Lancet |volume=2 |issue=8447 |pages=161 | date=July  1985 |pmid=2862357 |doi= 10.1016/s0140-6736(85)90270-3|url= }}<!--|accessdate=2014-09-24--></ref>

== Contraindications ==
Enoxacin is contraindicated in subjects with a history of [[hypersensitivity]] to the substance or any other member of the quinolone class, or any component of the medicine. Enoxacin, like other fluoroquinolones, can cause degenerative changes in weightbearing joints of young animals. The compound should only be used in children
when the expected benefits are outweigh the risks.<ref name="pmid12777590">{{cite journal |vauthors=Chalumeau M, Tonnelier S, D'Athis P, Tréluyer JM, Gendrel D, Bréart G, Pons G |title=Fluoroquinolone safety in pediatric patients: a prospective, multicenter, comparative cohort study in France |journal=Pediatrics |volume=111 |issue=6 Pt 1 |pages=e714–9 | date=June  2003 |pmid=12777590 |doi= 10.1542/peds.111.6.e714|url=http://pediatrics.aappublications.org/cgi/pmidlookup?view=long&pmid=12777590 |accessdate=2014-09-24}}</ref><ref name="pmid16951028">{{cite journal |title=The use of systemic fluoroquinolones |journal=Pediatrics |volume=118 |issue=3 |pages=1287–92 | date=September  2006 |pmid=16951028 |doi=10.1542/peds.2006-1722 |url=http://pediatrics.aappublications.org/cgi/pmidlookup?view=long&pmid=16951028 |accessdate=2014-09-24}}</ref>

== Interactions ==
* [[Fenbufen]]: co-administration with some quinolones, including enoxacin may increase the risk of seizures. For this reason, concomitant administration of fenbufen and the quinolone should be avoided, as a precaution.<ref name="pmid3216153">{{cite journal |vauthors=Morita H, Maemura K, Sakai Y, Kaneda Y |title=[A case of convulsion, loss of consciousness and subsequent acute renal failure caused by enoxacin and fenbufen] |language=Japanese |journal=Nippon Naika Gakkai Zasshi |volume=77 |issue=5 |pages=744–5 | date=May  1988 |pmid=3216153 |doi= 10.2169/naika.77.744|url= }}<!--|accessdate=2014-09-25--></ref><ref name="pmid1446880">{{cite journal |vauthors=Hara Y, Ally A, Suzuki T, Murayama S |title=[Effects of drugs on the convulsions induced by the combination of a new quinolone antimicrobial, enoxacin, and a nonsteroidal anti-inflammatory drug, fenbufen, in mice] |language=Japanese |journal=Nippon Yakurigaku Zasshi |volume=100 |issue=4 |pages=301–5 | date=October  1992 |pmid=1446880 |doi= 10.1254/fpj.100.301|url= }}<!--|accessdate=2014-09-25--></ref><ref name="pmid9623721">{{cite journal |vauthors=Masukawa T, Nakanishi K, Natsuki R |title=Role of nitric oxide in the convulsions following the coadministration of enoxacin with fenbufen in mice |journal=Jpn. J. Pharmacol. |volume=76 |issue=4 |pages=425–9 | date=April  1998 |pmid=9623721 |doi= 10.1254/jjp.76.425|url=http://joi.jlc.jst.go.jp/JST.JSTAGE/jjp/76.425?from=PubMed |accessdate=2014-09-25}}</ref><ref name="pmid9074952">{{cite journal |vauthors=Masukawa T, Nakanishi K |title=Circadian variation in enoxacin-induced convulsions in mice coadministered with fenbufen |journal=Jpn. J. Pharmacol. |volume=73 |issue=2 |pages=175–7 | date=February  1997 |pmid=9074952 |doi= 10.1254/jjp.73.175|url=http://joi.jlc.jst.go.jp/JST.Journalarchive/jphs1951/73.175?from=PubMed |accessdate=2014-09-25}}</ref>
* [[Theophylline]]: in patients treated concurrently with theophylline and enoxacin, concentrations of the [[methylxanthine]] in plasma arise due to a reduced metabolic clearance of theophylline.<ref name="pmid6145999">{{cite journal |vauthors=Wijnands WJ, van Herwaarden CL, Vree TB |title=Enoxacin raises plasma theophylline concentrations |journal=Lancet |volume=2 |issue=8394 |pages=108–9 | date=July  1984 |pmid=6145999 |doi= 10.1016/s0140-6736(84)90283-6|url= }}<!--|accessdate=2014-09-25--></ref><ref name="pmid3477409">{{cite journal |vauthors=Niki Y, Soejima R, Kawane H, Sumi M, Umeki S |title=New synthetic quinolone antibacterial agents and serum concentration of theophylline |journal=Chest |volume=92 |issue=4 |pages=663–9 | date=October  1987 |pmid=3477409 |doi= 10.1378/chest.92.4.663|url=http://journal.publications.chestnet.org/article.aspx?volume=92&page=663 |accessdate=2014-09-25}}</ref><ref name="pmid8843297">{{cite journal |vauthors=Mizuki Y, Fujiwara I, Yamaguchi T, Sekine Y |title=Structure-related inhibitory effect of antimicrobial enoxacin and derivatives on theophylline metabolism by rat liver microsomes |journal=Antimicrob. Agents Chemother. |volume=40 |issue=8 |pages=1875–80 | date=August  1996 |pmid=8843297 |pmc=163433 |doi= |url=http://aac.asm.org/cgi/pmidlookup?view=long&pmid=8843297 |accessdate=2014-09-25}}</ref><ref name="pmid3191935">{{cite journal |vauthors=Sano M, Kawakatsu K, Ohkita C, Yamamoto I, Takeyama M, Yamashina H, Goto M |title=Effects of enoxacin, ofloxacin and norfloxacin on theophylline disposition in humans |journal=Eur. J. Clin. Pharmacol. |volume=35 |issue=2 |pages=161–5 |year=1988 |pmid=3191935 |doi= 10.1007/bf00609246|url= }}<!--|accessdate=2014-09-25--></ref>
* [[Ranitidine]], [[sucralfate]], [[antacids]] containing [[magnesium]] or [[aluminum]], supplements containing [[calcium]], [[iron]], or [[zinc]]: co-administration with these substances can lead to therapeutic failure of the antibiotic due to decreased absorbment by the intestinal tract. For example, magnesium or aluminum antacids turn enoxacin into insoluble salts that are not readily absorbed by the gastroenteric tract.<ref name="pmid2751276">{{cite journal |vauthors=Grasela TH, Schentag JJ, Sedman AJ, Wilton JH, Thomas DJ, Schultz RW, Lebsack ME, Kinkel AW |title=Inhibition of enoxacin absorption by antacids or ranitidine |journal=Antimicrob. Agents Chemother. |volume=33 |issue=5 |pages=615–7 | date=May  1989 |pmid=2751276 |pmc=172500 |doi= 10.1128/aac.33.5.615|url=http://aac.asm.org/cgi/pmidlookup?view=long&pmid=2751276 |accessdate=2014-09-25}}</ref><ref name="pmid8494374">{{cite journal |vauthors=Nix DE, Lebsack ME, Chapelsky M, Sedman AJ, Busch J, Norman A |title=Effect of oral antacids on disposition of intravenous enoxacin |journal=Antimicrob. Agents Chemother. |volume=37 |issue=4 |pages=775–7 | date=April  1993 |pmid=8494374 |pmc=187758 |doi= 10.1128/aac.37.4.775|url=http://aac.asm.org/cgi/pmidlookup?view=long&pmid=8494374 |accessdate=2014-09-25}}</ref><ref name="pmid8429114">{{cite journal |vauthors=Misiak PM, Eldon MA, Toothaker RD, Sedman AJ |title=Effects of oral cimetidine or ranitidine on the pharmacokinetics of intravenous enoxacin |journal=J Clin Pharmacol |volume=33 |issue=1 |pages=53–6 | date=January  1993 |pmid=8429114 |doi= 10.1002/j.1552-4604.1993.tb03903.x|url=http://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0091-2700&date=1993&volume=33&issue=1&spage=53 |accessdate=2014-09-25}}</ref>

==Notes==
{{reflist|group=note}}

==References==
<references />

==Additional reading==
*{{cite journal | pmid = 8741236 | last1 = Patel  | first1 = SS | last2 = Spencer | first2 = CM | title = Enoxacin: a reappraisal of its clinical efficacy in the treatment of genitourinary tract infections | journal = Drugs| volume=51 | issue=1 |date=January 1996 | pages=137–60 | doi=10.2165/00003495-199651010-00009}}.

==External links==
*[http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a692043.html Medline entry]

{{QuinoloneAntiBiotics}}

[[Category:Fluoroquinolone antibiotics]]
[[Category:Withdrawn drugs]]
[[Category:Naphthyridines]]
[[Category:Piperazines]]
[[Category:Carboxylic acids]]